Dr. Agarwal's Eye (DRAGARWQ) | Financial Analysis & Statements
Dr. Agarwal's Eye Hospital Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
1.2B
Gross Profit
907.8M
77.64%
Operating Income
265.5M
22.71%
Net Income
172.6M
14.76%
EPS (Diluted)
₹36.72
Balance Sheet Metrics
Total Assets
6.1B
Total Liabilities
4.0B
Shareholders Equity
2.1B
Debt to Equity
1.93
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Dr. Agarwal's Eye Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.9B | 3.2B | 2.7B | 2.0B | 1.4B |
| Cost of Goods Sold | 896.2M | 1.3B | 1.1B | 851.5M | 646.7M |
| Gross Profit | 3.0B | 1.8B | 1.5B | 1.2B | 748.9M |
| Gross Margin % | 77.2% | 57.6% | 57.2% | 57.6% | 53.7% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 739.3M | 650.5M | 524.7M | 374.2M | 273.1M |
| Other Operating Expenses | 307.7M | 223.5M | 215.4M | 170.9M | 147.8M |
| Total Operating Expenses | 1.0B | 874.0M | 740.1M | 545.1M | 420.9M |
| Operating Income | 813.3M | 677.4M | 564.7M | 382.7M | 107.7M |
| Operating Margin % | 20.6% | 21.4% | 21.2% | 19.0% | 7.7% |
| Non-Operating Items | |||||
| Interest Income | 8.2M | 19.5M | 7.8M | 5.4M | 1.3M |
| Interest Expense | 123.6M | 71.0M | 68.0M | 61.2M | 61.3M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 707.0M | 622.5M | 494.0M | 323.1M | 57.3M |
| Income Tax | 160.5M | 158.9M | 124.8M | 82.1M | 71.7M |
| Effective Tax Rate % | 22.7% | 25.5% | 25.3% | 25.4% | 125.1% |
| Net Income | 546.5M | 463.6M | 369.2M | 241.0M | -14.4M |
| Net Margin % | 13.9% | 14.6% | 13.8% | 12.0% | -1.0% |
| Key Metrics | |||||
| EBITDA | 1.2B | 964.0M | 765.8M | 586.0M | 298.4M |
| EPS (Basic) | ₹116.28 | ₹98.64 | ₹78.55 | ₹51.29 | ₹-3.06 |
| EPS (Diluted) | ₹116.28 | ₹98.64 | ₹78.55 | ₹51.29 | ₹-3.06 |
| Basic Shares Outstanding | 4700000 | 4700000 | 4700000 | 4700000 | 4700000 |
| Diluted Shares Outstanding | 4700000 | 4700000 | 4700000 | 4700000 | 4700000 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Dr. Agarwal's Eye Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 111.6M | 328.8M | 273.8M | 281.1M | 215.2M |
| Short-term Investments | 126.3M | 100.0K | 28.3M | 44.6M | 69.4M |
| Accounts Receivable | 139.7M | 129.3M | 101.1M | 86.7M | 87.8M |
| Inventory | 134.0M | 97.5M | 60.0M | 57.3M | 52.1M |
| Other Current Assets | 15.6M | 14.5M | 2.2M | 30.4M | 2.5M |
| Total Current Assets | 559.4M | 598.3M | 465.4M | 500.0M | 440.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.4B | 1.1B | 824.3M | 649.1M | 553.6M |
| Goodwill | 337.5M | 9.8M | 13.2M | 18.3M | 6.1M |
| Intangible Assets | 224.3M | 6.2M | 9.6M | 14.7M | 6.1M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 143.2M | 43.3M | -100.0K | 100.0K | 7.2M |
| Total Non-Current Assets | 5.6B | 4.4B | 3.4B | 2.6B | 1.1B |
| Total Assets | 6.1B | 5.0B | 3.9B | 3.1B | 1.6B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 302.0M | 318.4M | 266.9M | 256.7M | 178.3M |
| Short-term Debt | 275.3M | 199.7M | 187.3M | 163.3M | 190.2M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 29.1M | 21.9M | 19.9M | 18.4M | 17.2M |
| Total Current Liabilities | 869.8M | 807.7M | 550.8M | 533.5M | 486.0M |
| Non-Current Liabilities | |||||
| Long-term Debt | 3.1B | 2.5B | 2.1B | 1.8B | 485.2M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 3.2B | 2.6B | 2.2B | 1.8B | 519.7M |
| Total Liabilities | 4.0B | 3.4B | 2.8B | 2.4B | 1.0B |
| Equity | |||||
| Common Stock | 47.0M | 47.0M | 47.0M | 47.0M | 47.0M |
| Retained Earnings | 2.0B | 1.5B | 1.0B | 671.3M | 436.2M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 2.1B | 1.6B | 1.1B | 781.7M | 546.6M |
| Key Metrics | |||||
| Total Debt | 3.3B | 2.7B | 2.3B | 1.9B | 675.5M |
| Working Capital | -310.4M | -209.4M | -85.4M | -33.5M | -45.3M |
Balance Sheet Composition
Dr. Agarwal's Eye Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 707.0M | 622.5M | 494.0M | 241.0M | -14.4M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -77.1M | 16.0M | 25.1M | -22.2M | -15.7M |
| Operating Cash Flow | 738.7M | 673.0M | 576.5M | 279.5M | 32.1M |
| Investing Activities | |||||
| Capital Expenditures | 4.1M | 10.0M | 700.0K | -464.1M | -110.2M |
| Acquisitions | -184.8M | - | - | - | - |
| Investment Purchases | -117.5M | - | - | -249.0K | -67.0K |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -299.8M | 5.0M | -4.3M | -464.6M | -110.3M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -23.5M | -25.8M | -14.1M | -200.0K | -358.0K |
| Debt Issuance | 561.8M | 150.0M | 209.4M | 257.5M | 43.2M |
| Debt Repayment | -111.3M | -75.3M | -90.5M | -184.4M | -78.6M |
| Financing Cash Flow | 427.0M | 48.9M | 23.7M | 64.2M | -15.1M |
| Free Cash Flow | -83.8M | 184.5M | -7.2M | 99.5M | 226.9M |
| Net Change in Cash | 865.9M | 726.9M | 595.9M | -120.9M | -93.3M |
Cash Flow Trend
Dr. Agarwal's Eye Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
34.01
Forward P/E
516.77
Price to Book
7.52
Price to Sales
5.39
PEG Ratio
1.81
Profitability Ratios
Profit Margin
15.50%
Operating Margin
19.54%
Return on Equity
26.07%
Return on Assets
8.91%
Financial Health
Current Ratio
0.64
Debt to Equity
106.45
Beta
-0.57
Per Share Data
EPS (TTM)
₹147.68
Book Value per Share
₹668.22
Revenue per Share
₹951.73
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| DRAGARWQ | 24.3B | 34.01 | 7.52 | 26.07% | 15.50% | 106.45 |
| Apollo Hospitals | 1.1T | 61.08 | 12.11 | 16.71% | 7.44% | 83.61 |
| Max Healthcare | 979.8B | 68.81 | 9.77 | 11.47% | 17.43% | 32.58 |
| Indraprastha Medical | 37.3B | 20.08 | 5.57 | 26.98% | 12.60% | 4.76 |
| Shalby | 16.7B | 207.28 | 1.75 | 0.63% | 0.72% | 53.32 |
| KMC Speciality | 14.6B | 40.06 | 8.09 | 13.04% | 12.88% | 47.30 |
Financial data is updated regularly. All figures are in the company's reporting currency.





